Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. - Wikidata - awgldk - TriplyDB

Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.

Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.

http://www.wikidata.org/entity/Q33815573

about

Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.

http://www.wikidata.org/entity/Q33815573

description

2017 nî lūn-bûn

@nan

2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@ast

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@en

type

label

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@ast

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@en

prefLabel

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@ast

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@en

P1433

Q33815573-5B91F1C6-EBAE-45DA-88E0-29C58CE5053E

P1476

Q33815573-88877826-313A-49D8-BCC3-CBBA72FD6235

P2093

Q33815573-85A3E66F-6C9D-4704-934F-F3F76B7E6594

Q33815573-ADA82EFE-C9E2-4887-ACB6-0A96A23C13AD

Q33815573-BAD13C5F-3EE2-48F4-8BF4-C5D52313267A

P2860

Q33815573-016F6F2C-8505-427C-A995-F79D1832E73C

Q33815573-0189C42F-63B3-490D-909D-2DC383B64150

Q33815573-03A9F062-A64E-4454-8317-E5F936C26073

Q33815573-064C433D-BB1A-4DD2-B2DC-BF9938368AF3

Q33815573-087CDD5C-79B9-481C-A431-6FE64D80F955

Q33815573-099A6224-3CE9-40EC-BC5E-B127366676F3

Q33815573-0AD31689-C55D-40BA-88FE-58BD26AE2BBC

Q33815573-0CD7CBFA-8AC8-4206-AB83-BFD588DD0994

Q33815573-1028C85E-588A-4C55-B8BB-10A1701610B0

Q33815573-14B83962-0A0E-4871-8F67-E40795860424

P304

Q33815573-A8BE4586-B53F-4689-8699-3A57ACEAEF94

P31

Q33815573-3D179302-73C1-4084-A7F1-E09CEE0B9AA6

P356

Q33815573-EEF4543B-371D-4C0C-98C1-72D5C7CAC984

P433

Q33815573-5E6E0DE8-0FBD-49D2-96AE-B864E3A40D89

P478

Q33815573-B71039A4-9973-44C6-BB47-A979CC4EF055

P577

Q33815573-A7CB3999-E56D-4790-9E12-8B8FB57F0CA8

P698

Q33815573-B7CE89B3-DB93-49E9-A073-18CC42EE4627

P921

Q33815573-294DB04C-AFBB-478E-8969-C2EDC80AE87F

P932

Q33815573-579A62CD-A135-4508-83C9-48EDDD6405E0

P356

IJEM.IJEM_442_16

P1433

Indian Journal of Endocrinology and Metabolism

P1476

Dose Modification of Antidiabe ...... es Mellitus and Heart Failure.

@en

P2093

Arthur Asirvatham

http://www.w3.org/2001/XMLSchema#string

D C Sharma

http://www.w3.org/2001/XMLSchema#string

Parminder Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Beneficial haemodynamic effects of insulin in chronic heart failure

P304

618-629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJEM.IJEM_442_16

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28670548

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5477452

http://www.w3.org/2001/XMLSchema#string